Age Modifies Impact of Resting Heart Rate on Death, CV Events

Share this content:
Age Modifies Impact of Resting Heart Rate on Death, CV Events
Age Modifies Impact of Resting Heart Rate on Death, CV Events

MONDAY, Jan. 23, 2017 (HealthDay News) -- The effect of resting heart rate (RHR) on all-cause mortality and cardiovascular events varies with age, according to a study published online Dec. 30 in the Journal of the American Geriatrics Society.

Kuibao Li, M.D., from Capital Medical University in Beijing, and colleagues conducted a prospective cohort study involving 6,209 individuals aged 40 years and older without cardiovascular disease at baseline. Participants were interviewed in 1991 using a standard questionnaire to obtain information on demographics, medical history, and lifestyle risk factors. RHR was categorized according to quartiles.

The researchers found that 840 subjects died and 676 experienced a cardiovascular event during a mean follow-up of 8.3 years. In older participants (≥60 years), there was a significant association for higher RHR with all-cause mortality (P trend < 0.001) and cardiovascular events (P trend = 0.002), which was not seen in younger participants (<60 years; both P trend > 0.05). Age had a significant modifying effect on the correlation between RHR and all-cause mortality and cardiovascular events (P interaction < 0.001 and P interaction = 0.002, respectively). After exclusion of individuals who died or had a cardiovascular event during the first two years of follow-up the results were similar.

"High RHR appears to be an independent determinant of all-cause mortality and cardiovascular events in older but not younger individuals," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »